Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: A cardiovascular magnetic resonance study

Clinical and Experimental Hypertension

Volumn 37, Issue 4, 2015, Pages 308-316

  Ripley, David P ^a   Negrou, Kalliopi ^a   Oliver, James J ^a   Worthy, Gill ^b   Struthers, Allan D ^c   Plein, Sven ^a   Greenwood, John P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Aortic stiffness; Arterial stiffness; Cardiovascular magnetic resonance; Hypertension; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; BENDROFLUMETHIAZIDE; MOXONIDINE; VALSARTAN; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE;

ADRENERGIC SYSTEM; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AORTIC REMODELLING; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR REMODELING; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; HEART VENTRICLE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; THORACIC AORTA; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BENDROFLUMETHIAZIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; SYMPATHOLYTICS; TREATMENT OUTCOME; VALSARTAN; VASCULAR REMODELING; VASCULAR STIFFNESS;

EID: 84943553600     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2014.960974     Document Type: Article

References (56)

1. Lehmann ED. Clinical value of aortic pulse-wave velocity measurement. Lancet 1999;354:528-9.
2. Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation 1989;80:78-86.
3. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664-70.
4. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113:657-63.
5. Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003;34:1203-6.
6. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-5.
7. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
8. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;111:3384-90.
9. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106:2085-90.
10. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434-9.
11. Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32:570-4.
12. Metafratzi ZM, Efremidis SC, Skopelitou AS, De Roos A. The clinical significance of aortic compliance and its assessment with magnetic resonance imaging. J Cardiovasc Magn Reson 2002;4: 481-91.
13. Nelson AJ, Worthley SG, Cameron JD, et al. Cardiovascular magnetic resonance-derived aortic distensibility: validation and observed regional differences in the elderly. J Hypertens 2009;27: 535-42.
14. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001;38:1711-17.
15. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.
16. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992;5: 182S-9.
17. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
18. Burns J, Ball SG, Worthy G, et al. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens 2012; 30:2039-46.
19. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005;45:426-31.
20. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988;78: 941-50.
21. De Luca N, Ricciardelli B, Rosiello G, et al. Stable improvement in large artery compliance after long-term antihypertensive treatment with enalapril. Am J Hypertens 1988;1:181-3.
22. De Luca N, Rosiello G, Lamenza F, et al. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Cardiol 1992;70: 52D-9.
23. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-23.
24. Richer C, Mulder P, Fornes P, et al. Hemodynamic and morphological effects of quinapril during genetic hypertension development. J Cardiovasc Pharmacol 1991;18:631-42.
25. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 1991;18:132-41.
26. Stewart AD, Jiang B, Millasseau SC, et al. Acute reduction of blood pressure by nitroglycerin does not normalize large artery stiffness in essential hypertension. Hypertension 2006;48:404-10.
27. Alfakih K, Plein S, Thiele H, et al. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 2003;17:323-9.
28. Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007;115:1999-2005.
29. Lorenz CH, Walker ES, Morgan VL, et al. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1999; 1:7-21.
30. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003;23:554-66.
31. Lip GY. Regression of left ventricular hypertrophy and improved prognosis: some hope now or hype? Circulation 2001;104:1582-4.
32. Sutton-Tyrrell K, Newman A, Simonsick EM, et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001; 38:429-33.
33. Mitchell GF, Guo CY, Benjamin EJ, et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation 2007;115:2628-36.
34. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
35. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
36. Dogui A, Kachenoura N, Frouin F, et al. Consistency of aortic distensibility and pulse wave velocity estimates with respect to the Bramwell-Hill theoretical model: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2011;13:11.
37. Benetos A. Pulse pressure and cardiovascular risk. J Hypertens Suppl 1999;17:S21-4.
38. Nichols WW, Edwards DG. Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther 2001;6: 5-21.
39. Nussbacher A, Gerstenblith G, O'Connor FC, et al. Hemodynamic effects of unloading the old heart. Am J Physiol 1999;277: H1863-71.
40. Urschel CW, Covell JW, Sonnenblick EH, et al. Effects of decreased aortic compliance on performance of the left ventricle. Am J Physiol 1968;214:298-304.
41. Levy BI, Curmi P, Poitevin P, Safar ME. Modifications of the arterial mechanical properties of normotensive and hypertensive rats without arterial pressure changes. J Cardiovasc Pharmacol 1989;14:253-9.
42. Levy BI, Poitevin P, Safar ME. Effects of indapamide on the mechanical properties of the arterial wall in deoxycorticosterone acetate-salt hypertensive rats. Am J Cardiol 1990;65:28H-32.
43. Breithaupt-Grogler K, Leschinger M, Belz GG, et al. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc Drugs Ther 1996;10:49-57.
44. Weir MR. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. J Hum Hypertens 2007;21:770-9.
45. Benetos A, Vasmant D, Thiery P, Safar M. Effects of ramipril on arterial hemodynamics. J Cardiovasc Pharmacol 1991;18:S153-6.
46. Scalbert E, Levy B, Desche P, et al. Vascular effects of perindopril: from experimental to clinical investigation. J Cardiovasc Pharmacol 1991;18:S25-32.
47. Barenbrock M, Spieker C, Hoeks AP, et al. Effect of lisinopril and metoprolol on arterial distensibility. Hypertension 1994;23:I161-3.
48. Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990; 15:68-77.
49. Levy BI, Michel JB, Salzmann JL, et al. Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats. J Hypertens Suppl 1988;6:S23-5.
50. Tornig J, Amann K, Ritz E, et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996;7:667-75.
51. Dorresteijn JA, Schrover IM, Visseren FL, et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebocontrolled cross-over trial. J Hypertens 2013;31:393-403.
52. Shirai K, Utino J, Saiki A, et al. Evaluation of blood pressure control using a new arterial stiffness parameter, cardio-ankle vascular index (CAVI). Curr Hypertens Rev 2013;9:66-75.
53. Komai N, Ohishi M, Moriguchi A, et al. Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002;25:5-10.
54. de la Chica-Rodriguez S, Cortes-Denia P, Ramirez-Exposito MJ, Martinez-Martos JM. Effects of alpha1-adrenergic receptor blockade by doxazosin on renin-angiotensin systemregulating aminopeptidase and vasopressin-degrading activities in male and female rat thalamus. Horm Metab Res 2007;39:813-17.
55. Honda T, Yano K, Matsuoka H, et al. Evaluation of aortic distensibility in patients with essential hypertension by using cine magnetic resonance imaging. Angiology 1994;45: 207-12.
56. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92.